← All trials
NCT01955187
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2014
- Primary completion
- Dec 1, 2018
- Completion date
- Apr 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 106
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Universidad Complutense de MadridLead sponsor
- University of BarcelonaOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- Hospital general Universitario de Ciudad RealOverall official - principal investigator
- Radboud UniversityOverall official - principal investigator
- Hospital Universitario Fundación AlcorcónCollaborator
- Biobanco REDinRENCollaborator
- RWTH Aachen UniversityCollaborator
- European Renal AssociationCollaborator
- Universidad Complutense de MadridReponsible party - principal investigator
- Fundación Puigvert, BarcelonaOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- Hospital Universitario Fundación AlcorcónOverall official - principal investigator
- Universidad Autonoma de MadridCollaborator
- Universidad Complutense de MadridOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.